Compass Pathways Surges Premarket on Accelerated FDA Review for Psilocybin Drug
Compass Pathways shares surged 19.5% in premarket trading after the FDA cleared a faster review path for its COMP360 psilocybin depression treatment. The company will discuss next steps at the RBC Capital Markets conference.
Markets
